Europe
On Monday, a judge ruled against patents blocking the way for generic drugmakers Hikma Pharmaceuticals and Dr. Reddy’s Laboratories to file Abbreviated New Drug Applications for Vascepa generics.
The two companies will work to develop up to four preclinical compounds discovered by Sitryx for autoimmune diseases.
4BIO Capital, an international venture capital firm focused solely on the advanced therapies sector, announces its investment in Redpin Therapeutics, Inc., a pioneering chemogenetics company developing drug-controlled gene therapies to address intractable diseases of the nervous system.
evitria AG, a global antibody expression service provider, announces that it has crossed the 100-citation threshold on Google Scholars.
Collaboration with Silence Therapeutics aims to develop novel, targeted treatments to address significant unmet need
AstraZeneca’s Farxiga could be closer to securing approval as a treatment for chronic kidney disease.
Cobra Biologics and the Karolinska Institutet, secured millions in emergency funding from Horizon 2020 to support research and development and an eventual Phase I clinical trial testing of a DNA vaccine against COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 30, 2020.
Heidelberg Pharma AG announced that a scientific article on the chemical synthesis of the fungal compound Amanitin has been published in Angewandte Chemie, a leading chemical journal.
Pioneering new technologies for resetting the immune system, developing novel, first-in-class therapies for inflammatory and immunological diseases
PRESS RELEASES